



A comparison of epidural levobupivacaine 0.5% with racemic bupivacaine 0.5 % for lower abdominal surgery

Ravi Shruthi¹, Nimmi Raj²

¹ Consultant Anaesthetist, Sanjeevini Hospital, Bellary, Karnataka, India

² Assistant Professor, Govt. Medical College, Trivandrum, Kerala, India

Abstract

- Racemic bupivacaine has been widely used as a local anesthetic because of its long duration of action and beneficial ratio of sensory to motor block when used for epidural analgesia.
- However, there have been reports of death attributable to bupivacaine-induced cardio toxicity in patients after accidental intravascular injection.

Keywords: Levobupivacaine Bupivacaine Cardiotoxic Epidural Analgesia

Introduction

Levobupivacaine

The isolated S (-) isomer of bupivacaine,

- Has been shown to be less cardiotoxic than bupivacaine in preclinical studies.
- Initial studies with levobupivacaine are now appearing in the literature confirming its equivalent clinical efficacy with racemic bupivacaine.

Objective of the study

- We compared the clinical efficacy (onset, duration, and intraoperative conditions) and tolerability of 0.5% levobupivacaine with that of 0.5% bupivacaine in patients undergoing elective lower abdominal surgery with epidural anesthesia.

Methodology

- 60 patients, belonging to ASA grade I or II, aged between 18 to 60 years, undergoing elective lower abdominal surgeries were randomly selected (chit method).
- Informed consent was taken.
- The study population was randomly divided into two groups with 30 patients in each group.
- Study group L - would receive 0.5% levobupivacaine
- Study group R - would receive 0.5% racemic bupivacaine
- Total Drug Given
- 17 ml of 0.5% levobupivacaine or 0.5% bupivacaine

Total Drug Given

- 17 ml of 0.5% levobupivacaine or 0.5% bupivacaine

Inclusion criteria

- Age group of 18-60 years of both sexes.
- ASA grade I or II.
- Patients coming for elective surgeries.
- Patients with SBP: 100-139 mm of Hg.
- Patients with DBP: 60-89 mm of Hg.

Exclusion Criteria

- Patient refusal.
- ASA grade III and IV.
- Patients with infection at site of injection.
- Patient with coagulopathy.
- Patients on anti-coagulation treatment (INR >1.5).
- Patients with congenital abnormalities of lower spine and meninges.
- Patients with history of severe renal, hepatic, respiratory, or cardiac disease or a neurological, neuromuscular, or psychiatric condition.

- Patients with history of allergy to local anaesthetics.
- Patients with uncontrolled systemic illness like diabetes mellitus, hypertension etc.
- Patients with uncorrected hypovolemia.
- Patients posted for lower segment caesarean section

Procedure

- Anaesthetic evaluation on the previous day of surgery
- Drug and equipments necessary for resuscitation and general anaesthesia were kept ready
- IV line was secured using 18G cannula and infusion started. Base line blood pressure, heart rate and respiratory rate was noted.
- The patient was placed in left lateral position
- Once the epidural space was confirmed
- 3ml of 2% Lignocaine with adrenaline 1:200000 was given as a test dose.
- Following which the study drug was given.

Parameters Monitored

- Onset of sensory block
- Degree of motor blockade – using Modified Bromage scale
- Duration of analgesia
- Haemodynamic changes- heart rate, blood pressure, mean arterial pressure and respiratory rate
- Intra operative and post-operative complications if any – such as nausea, vomiting, hypotension, bradycardia, respiratory depression was looked for, recorded and treated accordingly.

Statistical Methods

- Qualitative data will be analyzed by chi-square test.
- Quantitative data will be analyzed by student “t” test.

Results

Onset of Sensory Block




Fig 1

Table 1

Group L	Group R
11.6	12.4

Table 2

Group L	Group R
19.8	15.8

Onset of Motor Block




Fig 2

Table 3

	Group L	Group R
T6	63.3	60.0
T7	30.0	30.0
T10	6.7	10.0




Fig 3: Highest Level of Sensory Block

Degree of Motor Blockade




Fig 4

Table 4

Group L	Group R
286.6	281.6

Duration of motor block




Fig 5

Table 5

Group L	Group R
417.7	394.7

Duration of Sensory Analgesia




Fig 6

Hemodynamics




Fig 7





Fig 8

Table 6

	Group L	Group R
Nausea	3.3	6.7
Vomiting	0.0	3.3
Hypotension	6.7	10.0

Side Effects**Fig 9****Discussion**

- This study demonstrates that 0.5% levobupivacaine is a suitable anesthetic for use in lower abdominal surgery.
- Levobupivacaine provided
 1. Adequate sensory block
 2. Equivalent efficacy for the time taken to reach sensory block
 3. The sensory block is substantially longer than the motor block.
- In our study, levobupivacaine and bupivacaine both showed excellent sensory/motor separation.
- As expected, a decrease in systolic blood pressure, attributable to sympathetic block accompanying the epidural anesthesia, was the most common.

CVS and CNS toxicity

- Preclinical studies have shown that levobupivacaine has a reduced potential to cause cardiotoxic effects.
- The mild CNS symptoms developed at a larger dose level of levobupivacaine (56.1 mg) than with racemic bupivacaine (47.9 mg) when given intravenously.

Conclusion

- Levobupivacaine is being developed as a local anesthetic with a similar pharmacodynamic profile to racemic bupivacaine;
- The current study also demonstrates that 0.5% levobupivacaine provides sensory and motor block that is adequate for lower abdominal surgery; which is comparable to that achieved with the same volume and concentration of bupivacaine.
- **However, with less risk of systemic toxicity**
- (Which is desirable when using large dose of drug as in epidural anaesthesia.)

References

1. Dr Leon Visser, Dept. of Anesthesiology, University of Michigan Medical Center, Ann Arbor, Michigan, US. Epidural Anaesthesia, Practical Procedures, 2001, 13(3).
2. Albright G. Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. *Anesthesiology*, 1979;51:285-7.
3. Huang Y, Pryor M, Mather L, Veering B. Cardiovascular and central nervous system effects of intravenous levobupivacaine and bupivacaine in sheep. *Anesth Analg*, 1998;86:797-804.

4. Bardsley H, Gristwood R, Baker H, et al. A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers. *Br J Clin Pharmacol*,1998;46:245-9.
5. Cox C, Checketts M, Mackenzie N, et al. Comparison of S(2)- bupivacaine with racemic (RS)-bupivacaine in supraclavicular brachial plexus block. *Br J Anaesth*,1998;80:594–8.
6. Cox C, Faccenda K, Gilhooly C, et al. Extradural S(2)- bupivacaine: comparison with racemic RS-bupivacaine. *Br J Anaesth*,1998;80:289-93.
7. Kopacz DJ, Allen HW, Thompson GE, A comparison of epidural levobupivacaine 0.75% with racemic bupivacaine for lower abdominal surgery. *Anesth Analg*,2000;90(3):642-8.